Financials

Financials in One Page

MetLife is a $77B-revenue, $745B-asset global multi-line insurer that runs on insurance-spread economics: collect premiums, invest float across $500B+ of fixed-income and private credit, pay claims and benefits, and earn the difference. FY2025 revenue grew 8.6% to $77.1B on heavy U.S. pension-risk-transfer activity, but reported GAAP net income fell to $3.17B (vs $4.23B FY2024) because the new long-duration insurance accounting standard (LDTI, ASC 944, adopted FY2023) routes mark-to-market changes in policy reserves and deferred acquisition costs through GAAP operating income — producing the volatile, frequently-negative GAAP operating line you'll see in this page. The metric management and the sell-side actually price the stock on is adjusted earnings, which were a more stable $5.94B in FY2025 (+3.8% YoY). Cash conversion at the holding company is good: $4.4B of buybacks-plus-dividends was funded out of subsidiary distributions while the consolidated balance sheet stayed at investment-grade ratings. The stock at $78.94 trades at 16.8× GAAP P/E, ~9× adjusted P/E, and 1.82× book — slightly rich versus PRU (1.21×) and history (5-yr mean ~0.9×), reflecting the New Frontier plan that targets high-single-digit adjusted-EPS growth and a sub-19% expense ratio. The metric that matters most right now is adjusted earnings versus consensus, because it tells you whether the New Frontier targets are tracking and whether the post-LDTI volatility is masking a real margin reset or just accounting noise.

Revenue, Margins, and Earnings Power

What drives the top line. MetLife's revenue mix is roughly 70% premiums-and-fees and 30% net investment income. Premium growth comes from group benefits renewals, pension-risk-transfer transactions in Retirement & Income Solutions (RIS), and international new business in Asia and LatAm. Investment income moves with the size of the general account ($500B+) and the running yield on the bond book. Revenue is therefore not a pure top-line growth signal — large pension-risk-transfer deals can swell revenue without proportional earnings, because the premium is offset by an immediate increase in policy reserves.

Revenue has held a $60–77B band for fifteen years — slow-growth, scaled cash machine. The big 2011 jump came from acquiring Alico's international platform from AIG; the 2017 step-down reflects the Brighthouse Financial spinoff of the U.S. variable-annuity book. Net income is the signal to watch, not revenue. It collapsed in FY2016 (low rates + actuarial charges), in FY2023 (LDTI transition + impairments), and softened in FY2024–FY2025 (alternative-investment returns below long-term run-rate, accident-year strain in Group Benefits 1H25, taxes/Mexico VAT in LatAm).

Adjusted earnings — the operating view management runs the company on

The persistent gap is the cleanest tell that MetLife's underlying earnings power is more stable than the GAAP line suggests. Adjusted earnings have compounded +6.7% per year FY2023→FY2025 — modest, but in line with management's New Frontier target of high-single-digit adjusted-EPS growth.

Margin profile — why the GAAP "operating margin" is misleading

The optical "operating margin collapse" from FY2022 to FY2023 is not a business deterioration — it's the LDTI transition forcing market-driven changes in policy liabilities and DAC amortization through the income statement above the operating line. Look instead at ROE, which is calculated on actual common equity: it stayed in the 5–15% range throughout, hit 15.3% in FY2024, and printed 12.1% in FY2025 — at or slightly above MetLife's ~12% cost-of-equity. Net margin (4–10% over the cycle) and ROE are the right slice through the noise.

Recent quarterly trajectory

The 4Q25 revenue spike to $23.8B is a classic pension-risk-transfer (PRT) bulge — a mid-single-billion buy-out deal lands in revenue with an offsetting reserve build, so net income barely moved. 1Q26 is the inflection — revenue rebounded to $19.1B (+9% YoY), GAAP EPS climbed to $1.74, and adjusted EPS came in at $2.42 vs $2.27 consensus (+6.7% beat). Three consecutive quarterly misses in 2Q25/3Q25/4Q25 (-49%, -44%, but Q4 only –24%-ish on adjusted) reflected weaker private-equity returns and Group Benefits underwriting strain — both reversing in 1Q26.

Cash Flow and Earnings Quality

Free cash flow for an insurer is a trap concept. Operating cash flow at MetLife runs $11–17B/year because it includes net premiums received less benefits paid plus the build-up of policy reserves — that "cash" is not free; it's a contractual liability sitting on the balance sheet that will be paid out to policyholders over decades. The cash that actually accrues to common shareholders is the dividend distributions from regulated insurance subsidiaries up to the holding company, which run $4.5–5.5B per year. Levered free cash flow (after interest and required reinvestment) is the better proxy for "real" distributable cash.

The $4.4B returned to shareholders in FY2025 was funded out of $4.5–5.0B of subsidiary distributions to the holding company, plus $0.5B of net debt issuance — not out of the headline $17B OCF. That alignment is the most important earnings-quality test for a multi-line life insurer: capital returned ≈ subsidiary cash dividends ≈ adjusted earnings less corporate run-off losses. The ratio is healthy: $4.4B / $5.9B adjusted earnings = 74% capital-return ratio in FY2025, consistent with MET's long-term policy.

Balance Sheet and Financial Resilience

Insurers don't run on standard leverage metrics — total assets/equity is a function of policy reserves, not "debt". The right resilience tests are: (i) RBC ratio at the regulated insurance subsidiaries, (ii) the gap between fair-value investment portfolio and reserves, (iii) financial leverage at the holding company (financial debt to total capital), and (iv) credit ratings. MetLife scores well on all four.

The eye-catcher: shareholders' equity dropped from $74.8B (FY2020) to $30.1B (FY2022) and has stayed $27–30B since. This is not the company losing $45B of value — it's accumulated other comprehensive income (AOCI) flipping from a +$20B unrealized gain on the investment portfolio to a roughly -$25B unrealized loss as Treasury yields rose 400+bp during 2022. Retained earnings kept compounding ($28.9B → $44.3B FY2018→FY2025). For an insurer that holds bonds to maturity against matched liabilities, those AOCI swings have very limited economic meaning — but they did inflate book value before 2022 and now compress it. Tangible book value per share is the cleaner measure.

Tangible book has rebuilt from $25.45 (FY2022) to $27.90 (FY2025) and is compounding low-single-digits as AOCI marks normalize and retained earnings accrue. At $78.94, MET trades at 2.83× tangible book — well above the 2014–2020 range of 0.7–1.1× and above PRU's current ~0.9× tangible. The sharpest single valuation flag in the data.

Financial leverage and dividend coverage at the holding company

Financial leverage at the holding company sits in the low-20% range (target band 20–25%) and combined NAIC risk-based capital is well above the 360% Authorized Control Level — the regulatory framework that backs MetLife's A1 / A+ / A+ financial-strength ratings (Moody's / S&P / Best). Net debt is a small fraction of equity ($28.7B). The balance sheet is investment-grade-comfortable; refinancing risk is minimal across the next 24 months because of laddered maturities and consistent treasury access.

Returns, Reinvestment, and Capital Allocation

The capital story is the cleanest part of the financials. Share count is down 38% since FY2011 (from 1.06B to 0.66B), funded almost entirely from operating cash flow with no equity issuance. Combined dividend + buyback yield runs 9–10% per year, more than 3× the S&P 500 average.

The judgment: management is returning excess cash and re-investing in higher-margin Group Benefits, Asia, and MIM (asset management) — not chasing M&A in the U.S. retail life market that previously created the run-off Corporate & Other segment. The PineBridge Investments and Mesencéfalo acquisitions in FY2025 ($738M total) extend MIM's institutional asset-management footprint toward the $1T AUM target without bloating goodwill (intangibles are still only 1.3% of assets).

Segment and Unit Economics

Where the economics actually live: the U.S. business (Group Benefits + RIS) generated $3.36B of FY2025 adjusted earnings — over half the total. Asia at $1.70B is now MetLife's single largest segment by adjusted earnings, surpassing Group Benefits and RIS this year on +12.1% YoY growth. The growth weighting is shifting east. Latin America slipped (-8.1%) on Mexican VAT and tax-rate changes; EMEA is small and steady; MIM jumped +61% on AUM growth and a positive performance-fee contribution but is still only ~3% of group earnings. Corporate & Other (the run-off MetLife Holdings book — variable annuities, term/whole life, LTC) is a structural drag that's becoming smaller as the block runs off.

The geographic balance — roughly 52% U.S., 27% Asia, 13% LatAm, 6% EMEA, 3% asset management — is genuinely diversified. That diversity dampens any single-country macro shock, but it also caps the multiple the market is willing to pay vs. a pure-U.S. annuity peer like AFL.

Valuation and Market Expectations

The right valuation lens for a multi-line life insurer is price-to-tangible-book × ROE, anchored against historical and peer ranges. Secondary metric: forward adjusted P/E vs adjusted-EPS growth. Avoid GAAP P/E (volatile) and EV/EBITDA (negative on the LDTI basis and uninformative for an insurer regardless).

The optical P/B step-up from 0.76× (FY2021) to 1.89× (FY2022) is mostly denominator effect — equity collapsed from $67.7B to $30.1B on the AOCI swing, while market cap held. So the post-2022 P/B series is not directly comparable to the pre-2022 series. Compared to its own post-LDTI history, MET at 1.82× P/B today is roughly in line with the 1.6–2.1× FY2022–FY2024 range.

Forward adjusted P/E ≈ 9.0× on consensus FY2026 adjusted EPS of $9.88. That is genuinely cheap on an absolute basis — the S&P 500 trades over 21× — and consistent with the market pricing in low-single-digit terminal growth, persistent run-off drag, and rate-cycle risk to AOCI/book. But on price-to-tangible-book of 2.83×, the stock is not cheap relative to a 12% ROE business. The multiple expansion since 2021 implies the market gives credit to management's New Frontier plan; it does not leave room for execution slippage.

The base case ($94) lines up with the sell-side mean target ($90) and implies ~19% total return inclusive of dividend over twelve months. The bull case ($109) would require ROE to push toward 13–14% on a stable book, which means the FY2025 PE-return air pocket has to fully reverse and Group Benefits underwriting normalizes. The bear case ($69) would represent a multiple compression to the long-run pre-LDTI level — the path requires another rate shock that re-widens AOCI losses, or a meaningful adjusted-EPS miss vs the New Frontier plan.

Peer Financial Comparison

The peer gap that matters. MET is the only large multi-line in this set growing revenue (+8.6%) — every other peer's revenue contracted YoY, mostly on PRT timing or annuity de-risking. ROE of 12.1% is above the peer median. P/B of 1.82× sits between AFL's premium 1.94× (pure-supplemental-health, 13% ROE, lower-leverage business) and PRU's 1.21× (the most direct multi-line comp). MET's premium to PRU is justifiable — bigger Asia exposure, higher buyback yield, better diversification — but it is not obviously cheap. LNC at 0.78× P/B and 7.6× P/E is the clear peer-set value name — but for capital-adequacy reasons that don't apply to MET.

What to Watch in the Financials

What the financials confirm: MetLife is a scaled, diversified life-insurance compounder with healthy capital generation, a 38%-and-counting buyback record, and a rebuilding ROE that is back above cost-of-equity. Adjusted earnings and segment economics show genuine improvement in Group Benefits + Asia + MIM — the highest-margin, fastest-growing pieces of the portfolio.

What the financials contradict: the headline GAAP and EBITDA numbers say "this company has lost the ability to make money at the operating line" — they are wrong. The post-LDTI accounting volatility is a presentation issue, not an economic one. The 1.82× P/B and 2.83× P/TBV are not "cheap"; the cheapness is only in forward adjusted P/E (9×) and only if you trust the FY2026 consensus.

The first financial metric to watch is adjusted EPS versus consensus — specifically the FY2026 adjusted-EPS print versus the $9.88 mean estimate. A clean beat (>$10) validates New Frontier and supports the multiple-expansion case; a miss below $9.50 punctures the thesis and reopens the post-LDTI book-value debate.